研究热点和心力衰竭研究趋势的分析和预测
Zeye Liu1,2,3,4, Yuan Huang5, Yang Yang5
1Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.
Journal of translational internal medicine
|July 31, 2024
概括
这项研究分析了从1945年到2021年的270,617份心力衰竭出版物. 关键趋势包括医学中的人工智能,再生疗法和个性化患者护理,突出显示不断变化的研究前沿.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 生物医学研究生物医学研究
背景情况:
- 心力衰竭研究产生了广泛的数据,对学术见解和政策制定至关重要.
- 对1945年至2021年出版物的分析旨在确定心力衰竭文献中的研究主题,趋势和跨学科联系.
研究的目的:
- 识别和绘制心力衰竭文献中的研究主题和趋势.
- 了解随着时间的推移,心力衰竭研究的演变和跨领域性质.
- 突出该领域的新兴和利基研究领域.
主要方法:
- 利用人工智能技术从270,617个出版物标题和摘要中提取和集群文本片段.
- 采用了两个对结果可靠性和专家驱动主题和集群命名的验证算法.
- 计算了研究热点的年度词汇,以确定利基领域.
主要成果:
- 确定了107个不同的心力衰竭主题和16个主要文档集群,按时间划分.
- 临床研究正在扩大,其次是基础和人口研究.
- 关键主题包括重症监护,人工智能应用,心脏辅助设备,干细胞,遗传学,风险评分,健康经济学和再生医学.
结论:
- 临床和人口研究越来越多地关注个性化智能治疗和改善患者生活质量.
- 基础研究正在转向再生和转化医学,以及信号通路.
- 研究领域显示,由医疗需求,技术进步和社会支持驱动的融合日益增加.
更多相关视频
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Genome-wide Association Studies-GWAS
13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.3K


